Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis

被引:3
|
作者
Zhang, Suo [1 ,2 ]
Chen, Yu-Lan [1 ]
Liu, Cui-Lian [1 ]
Xie, Jing-Yi [1 ]
Sun, Bao-Dong [1 ]
Liu, Dong-Zhou [1 ]
机构
[1] Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Rheumatol & Immunol, Jinan Univ,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Peoples R China
[2] Shenzhen Second Peoples Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
IgA nephropathy; systemic autoimmune myopathies; dermatomyositis; anti- transcription intermediary factor-1 gamma antibody; dermatomyositis-specific antibodies; RENAL INVOLVEMENT; POLYMYOSITIS; AUTOANTIBODIES; SPECTRUM; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; RISK; LOCI;
D O I
10.3389/fimmu.2022.757802
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis characterized by IgA deposits in the mesangial area of glomeruli. Connective tissue disorders are some of the most frequent causes of secondary IgAN. Nevertheless, IgAN rarely occurs in systemic autoimmune myopathies (SAMs). The present case study reports on a 58-year-old patient with dermatomyositis with positive anti-transcription intermediary factor (TIF)-1 gamma antibodies who was diagnosed with IgAN during standard immunosuppressive therapy. Moreover, we have made a systematic review regarding the association of SAMs and IgAN. To the best of the authors' knowledge, this is the first case study describing a patient with anti-TIF1 gamma antibody-positive dermatomyositis who developed IgAN, which demonstrates a potential relationship between anti-TIF1 gamma-positive dermatomyositis and IgAN. It is important for clinicians to be aware of the possibility of renal involvement in patients with SAMs, even in those with anti-TIF1 gamma-positive dermatomyositis.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis: Reply
    Oldroyd, Alexander
    Sergeant, Jamie C.
    New, R. Paul
    McHugh, Neil J.
    Betteridge, Zoe
    Lamb, Janine A.
    Ollier, William E.
    Cooper, Robert G.
    Chinoy, Hector
    RHEUMATOLOGY, 2019, 58 (11) : 2073 - 2074
  • [42] SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-y, and Point Mutation in the Transcription Intermediary Factor 1-y Coding Gene: A Case Report
    Arnon, Johnathan
    Elia, Anna
    Nevo, Yuval
    Lossos, Alexander
    Nechushtan, Hovav
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (09):
  • [43] The Relationship Between Anti-Cell Division Cycle and Apoptosis Regulator 1 Autoantibodies, Anti-Sp4 Autoantibodies, and Cancer in Anti-Transcription Intermediary Factor 1γ-Positive Dermatomyositis
    Mecoli, Christopher A.
    Fiorentino, David
    Albayda, Jemima
    Paik, Julie J.
    Tiniakou, Eleni
    Adler, Brittany
    Mammen, Andrew L.
    Christopher-Stine, Lisa
    Rosen, Antony
    Casciola-Rosen, Livia
    ACR OPEN RHEUMATOLOGY, 2024, 6 (12) : 912 - 917
  • [44] Dramatic Improvement of Antitranscription Intermediary Factor-1-γ/α Antibody-Positive Dermatomyositis After Stereotactic Body Radiation Therapy to Presumed Lung Primary: A Case Report
    Kuczmarska-Haas, Aleksandra
    Burr, Adam R.
    Witt, Jacob S.
    Francis, David M.
    Ali, Hagger
    Sonneborn, Henry
    Mahadevan, Arul
    Brower, Jeffrey, V
    PRACTICAL RADIATION ONCOLOGY, 2020, 10 (06) : E551 - E556
  • [45] Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation
    Aggarwal, Rohit
    Oddis, Chester V.
    Goudeau, Danielle
    Fertig, Noreen
    Metes, Ilinca
    Stephens, Chad
    Qi, Zengbiao
    Koontz, Diane
    Levesque, Marc C.
    RHEUMATOLOGY, 2014, 53 (03) : 433 - 437
  • [46] IMMUNE CHECKPOINT INHIBITOR USE IN ANTI-TRANSCRIPTIONAL INTERMEDIARY FACTOR 1-GAMMA ANTIBODY-POSITIVE DERMATOMYOSITIS: WALKING ON THIN ICE?
    Chen, Liang
    Fallavollita, Sabrina
    Sakr, Lama
    Pollack, Michael N.
    Hudson, Marie
    Leclair, Valerie
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (02) : 558 - 558
  • [47] Anti-TIF1-γ antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer
    Li, J.
    Yi, S.
    Huang, Y.
    Peng, Y.
    Yang, Z.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 395 - 395
  • [48] Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis
    Motegi, Sei-ichiro
    Sekiguchi, Akiko
    Ikeuchi, Hidekazu
    Sakairi, Toru
    Ogawa, Hiroomi
    Fujii, Takaaki
    Sohda, Makoto
    Yajima, Toshiki
    Ida, Shota
    Takayasu, Yukihiro
    Shimoda, Yuki
    Hiromura, Keiju
    Saeki, Hiroshi
    Shirabe, Ken
    Chikamatsu, Kazuaki
    Yokoo, Hideaki
    Oyama, Tetsunari
    Ishikawa, Osamu
    JOURNAL OF DERMATOLOGY, 2020, 47 (12): : 1395 - 1402
  • [49] Anti-nuclear matrix protein 2 antibody-positive amyopathic dermatomyositis presenting in a patient with prostate cancer: A case report
    Shan, Divya M.
    Gupta, Neha
    Ortega-Loayza, Alex G.
    Shea, Sofia
    Nandan, Abhishek
    CLINICAL CASE REPORTS, 2024, 12 (05):
  • [50] Authors' reply to "a case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on the article by Mizumaki et al."
    Matsushita, Takashi
    Fushida, Natsumi
    Horii, Motoki
    Mizumaki, Kie
    JOURNAL OF DERMATOLOGY, 2023, 50 (07): : E228 - E229